1. Home
  2. KN vs CELC Comparison

KN vs CELC Comparison

Compare KN & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knowles Corporation

KN

Knowles Corporation

HOLD

Current Price

$36.89

Market Cap

3.0B

ML Signal

HOLD

Logo Celcuity Inc.

CELC

Celcuity Inc.

HOLD

Current Price

$123.46

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KN
CELC
Founded
1946
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
3.1B
IPO Year
2013
2017

Fundamental Metrics

Financial Performance
Metric
KN
CELC
Price
$36.89
$123.46
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$28.00
$112.56
AVG Volume (30 Days)
936.4K
961.0K
Earning Date
04-23-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
118.94
N/A
EPS
0.11
N/A
Revenue
$593,200,000.00
N/A
Revenue This Year
$9.40
N/A
Revenue Next Year
$6.98
$720.19
P/E Ratio
$335.82
N/A
Revenue Growth
7.17
N/A
52 Week Low
$16.09
$10.26
52 Week High
$37.08
$151.02

Technical Indicators

Market Signals
Indicator
KN
CELC
Relative Strength Index (RSI) 76.25 49.39
Support Level $23.56 $100.58
Resistance Level N/A $151.02
Average True Range (ATR) 1.29 8.22
MACD 0.39 -0.89
Stochastic Oscillator 98.35 38.88

Price Performance

Historical Comparison
KN
CELC

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: